{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:49:36Z","timestamp":1786981776345,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["Rector program, kakenhi grant 22H03027"],"award-info":[{"award-number":["Rector program, kakenhi grant 22H03027"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["453989101"],"award-info":[{"award-number":["453989101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["453989101"],"award-info":[{"award-number":["453989101"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["507803309"],"award-info":[{"award-number":["507803309"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum W\u00fcrzburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Recent studies investigating a tumor-sink effect in solid tumors reported on decreasing uptake in normal organs in patients with higher tumor burden. This phenomenon, however, has not been evaluated yet for theranostic radiotracers applied to hematological neoplasms. As such, we aimed to determine a potential \u201clymphoma-sink effect\u201d in patients with marginal zone lymphoma (MZL) imaged with C-X-C motif chemokine receptor (CXCR) 4-directed PET\/CTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Procedures<\/jats:title>\n                    <jats:p>\n                      We retrospectively analyzed 73 patients with MZL who underwent CXCR4-directed [\n                      <jats:sup>68<\/jats:sup>\n                      Ga]Ga-PentixaFor PET\/CT. Normal unaffected organ uptake (heart, liver, spleen, bone marrow, kidneys) was quantified using volumes of interests (VOIs) and mean standardized uptake values (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      ) were derived. MZL manifestations were also segmented to determine the maximum and peak standardized uptake values SUV (SUV\n                      <jats:sub>max\/peak<\/jats:sub>\n                      ) and volumetric parameters, including lymphoma volume (LV), and fractional lymphoma activity (FLA, defined as LV*SUV\n                      <jats:sub>mean<\/jats:sub>\n                      of lymphoma burden). This approach resulted in 666 VOIs to capture the entire MZL manifestation load. We used Spearman\u2019s rank correlations to determine associations between organ uptake and CXCR4-expressing lymphoma lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We recorded the following median SUV\n                      <jats:sub>mean<\/jats:sub>\n                      in normal organs: heart, 1.82 (range, 0.78\u20134.11); liver, 1.35 (range, 0.72\u20132.99); bone marrow, 2.36 (range, 1.12\u20134.83); kidneys, 3.04 (range, 2.01\u20136.37); spleen, 5.79 (range, 2.07\u201310.5). No relevant associations between organ radiotracer uptake and MZL manifestation were observed, neither for SUV\n                      <jats:sub>max<\/jats:sub>\n                      (\u03c1 \u2264 0.21,\n                      <jats:italic>P<\/jats:italic>\n                      \u2265 0.07), SUV\n                      <jats:sub>peak<\/jats:sub>\n                      (\u03c1 \u2264 0.20,\n                      <jats:italic>P<\/jats:italic>\n                      \u2265 0.09), LV (\u03c1 \u2264 0.13,\n                      <jats:italic>P<\/jats:italic>\n                      \u2265 0.27), nor FLA (\u03c1 \u2264 0.15,\n                      <jats:italic>P<\/jats:italic>\n                      \u2265 0.33).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Investigating a lymphoma-sink effect in patients with hematological neoplasms, we observed no relevant associations between lymphoma burden and uptake in normal organs. Those observations may have therapeutic implications, e.g., for \u201ccold\u201d SDF1-pathway disrupting or \u201chot,\u201d CXCR4-directed radiolabeled drugs, as with higher lymphoma load, normal organ uptake seems to remain stable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11307-023-01830-9","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T12:01:50Z","timestamp":1686139310000},"page":"758-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging"],"prefix":"10.1007","volume":"25","author":[{"given":"Aleksander","family":"Kosmala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Schneid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian E.","family":"Serfling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp E.","family":"Hartrampf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Buck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Duell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"1830_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.it.2007.05.007","volume":"28","author":"I Petit","year":"2007","unstructured":"Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28:299\u2013307","journal-title":"Trends Immunol"},{"key":"1830_CR2","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1007\/s00432-016-2220-6","volume":"142","author":"S Stollberg","year":"2016","unstructured":"Stollberg S, Kammerer D, Neubauer E et al (2016) Differential somatostatin and CXCR4 chemokine receptor expression in MALT-type lymphoma of gastric and extragastric origin. J Cancer Res Clin Oncol 142:2239\u20132247","journal-title":"J Cancer Res Clin Oncol"},{"key":"1830_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.120.257279","volume":"62","author":"J Duell","year":"2021","unstructured":"Duell J, Krummenast F, Schirbel A et al (2021) Improved primary staging of marginal-zone lymphoma by addition of CXCR4-directed PET\/CT. J Nucl Med 62:1415\u20131421","journal-title":"J Nucl Med"},{"key":"1830_CR4","first-page":"1687","volume":"63","author":"AK Buck","year":"2022","unstructured":"Buck AK, Haug A, Dreher N et al (2022) Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using (68)Ga-Pentixafor PET. J Nucl Med 63:1687\u20131692","journal-title":"J Nucl Med"},{"key":"1830_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2967\/jnumed.122.264207","volume":"64","author":"AK Buck","year":"2023","unstructured":"Buck AK, Grigoleit GU, Kraus S et al (2023) C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma. J Nucl Med 64:34\u201339","journal-title":"J Nucl Med"},{"key":"1830_CR6","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1007\/s00259-022-05849-y","volume":"49","author":"AK Buck","year":"2022","unstructured":"Buck AK, Serfling SE, Lindner T et al (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49:4133\u20134144","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1830_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.7150\/thno.21397","volume":"8","author":"S Habringer","year":"2018","unstructured":"Habringer S, Lapa C, Herhaus P et al (2018) Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics. Theranostics 8:369\u2013383","journal-title":"Theranostics"},{"key":"1830_CR8","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2967\/jnumed.121.261906","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Wang H, Robertson A et al (2022) Tumor sink effect in (68)Ga-PSMA-11 PET: myth or reality? J Nucl Med 63:226\u2013232","journal-title":"J Nucl Med"},{"key":"1830_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s11307-022-01717-1","volume":"24","author":"SE Serfling","year":"2022","unstructured":"Serfling SE, Lapa C, Dreher N et al (2022) Impact of tumor burden on normal organ distribution in patients imaged with CXCR4-targeted [(68)Ga]Ga-PentixaFor PET\/CT. Mol Imaging Biol 24:659\u2013665","journal-title":"Mol Imaging Biol"},{"key":"1830_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13550-019-0546-1","volume":"9","author":"M Oliveira","year":"2019","unstructured":"Oliveira M, Lasnon C, Nganoa C, Gac AC, Damaj G, Aide N (2019) Comprehensive analysis of the influence of G-CSF on the biodistribution of (18)F-FDG in lymphoma patients: insights for PET\/CT scheduling. EJNMMI Res 9:79","journal-title":"EJNMMI Res"},{"key":"1830_CR11","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-022-05977-5","volume":"50","author":"GJC Zwezerijnen","year":"2023","unstructured":"Zwezerijnen GJC, Eertink JJ, Ferrandez MC et al (2023) Reproducibility of [18F]FDG PET\/CT liver SUV as reference or normalisation factor. Eur J Nucl Med Mol Imaging 50:486\u2013493","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1830_CR12","first-page":"754","volume":"63","author":"H Hanscheid","year":"2022","unstructured":"Hanscheid H, Schirbel A, Hartrampf P et al (2022) Biokinetics and dosimetry of (177)Lu-Pentixather. J Nucl Med 63:754\u2013760","journal-title":"J Nucl Med"},{"issue":"11","key":"1830_CR13","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.3390\/cancers14112609","volume":"14","author":"A Kosmala","year":"2022","unstructured":"Kosmala A, Serfling SE, Dreher N et al (2022) Associations between normal organs and tumor burden in patients imaged with fibroblast activation protein inhibitor-directed positron emission tomography. Cancers (Basel) 14(11):2609","journal-title":"Cancers (Basel)"},{"key":"1830_CR14","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1007\/s11307-018-1293-9","volume":"21","author":"RA Werner","year":"2019","unstructured":"Werner RA, Hanscheid H, Leal JP et al (2019) Impact of tumor burden on quantitative [(68)Ga] DOTATOC biodistribution. Mol Imaging Biol 21:790\u2013798","journal-title":"Mol Imaging Biol"},{"key":"1830_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11307-019-01375-w","volume":"22","author":"RA Werner","year":"2020","unstructured":"Werner RA, Bundschuh RA, Bundschuh L et al (2020) Semiquantitative parameters in PSMA-targeted PET imaging with [(18)F]DCFPyL: impact of tumor burden on normal organ uptake. Mol Imaging Biol 22:190\u2013197","journal-title":"Mol Imaging Biol"},{"key":"1830_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/annonc\/mdn563","volume":"20","author":"E Boveri","year":"2009","unstructured":"Boveri E, Arcaini L, Merli M et al (2009) Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients. Ann Oncol 20:129\u2013136","journal-title":"Ann Oncol"},{"key":"1830_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2967\/jnumed.106.035774","volume":"48","author":"M Soret","year":"2007","unstructured":"Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932\u2013945","journal-title":"J Nucl Med"},{"key":"1830_CR18","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","volume":"61","author":"P Herhaus","year":"2020","unstructured":"Herhaus P, Lipkova J, Lammer F et al (2020) CXCR4-targeted PET imaging of central nervous system B-cell lymphoma. J Nucl Med 61:1765\u20131771","journal-title":"J Nucl Med"},{"key":"1830_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.2967\/jnumed.118.210997","volume":"60","author":"C Lapa","year":"2019","unstructured":"Lapa C, Hanscheid H, Kircher M et al (2019) Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med 60:60\u201364","journal-title":"J Nucl Med"},{"key":"1830_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11307-019-01376-9","volume":"22","author":"K Sahakyan","year":"2020","unstructured":"Sahakyan K, Li X, Lodge MA et al (2020) Semiquantitative parameters in PSMA-targeted PET imaging with [(18)F]DCFPyL: intrapatient and interpatient variability of normal organ uptake. Mol Imaging Biol 22:181\u2013189","journal-title":"Mol Imaging Biol"},{"key":"1830_CR21","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00259-011-1937-3","volume":"39","author":"JM Beauregard","year":"2012","unstructured":"Beauregard JM, Hofman MS, Kong G, Hicks RJ (2012) The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 39:50\u201356","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1830_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3322\/caac.21768","volume":"73","author":"EO Aboagye","year":"2023","unstructured":"Aboagye EO, Barwick TD, Haberkorn U (2023) Radiotheranostics in oncology: making precision medicine possible. CA Cancer J Clin 73(3):255\u2013274","journal-title":"CA Cancer J Clin"},{"key":"1830_CR23","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/cancers13235920","volume":"13","author":"M Schottelius","year":"2021","unstructured":"Schottelius M, Herrmann K, Lapa C (2021) In vivo targeting of CXCR4-new horizons. Cancers (Basel) 13:5920","journal-title":"Cancers (Basel)"},{"key":"1830_CR24","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.7150\/thno.19050","volume":"7","author":"C Lapa","year":"2017","unstructured":"Lapa C, Herrmann K, Schirbel A et al (2017) CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed Multiple Myeloma. Theranostics 7:1589\u20131597","journal-title":"Theranostics"},{"key":"1830_CR25","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","volume":"1","author":"SH Liu","year":"2017","unstructured":"Liu SH, Gu Y, Pascual B et al (2017) A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies. Blood Adv 1:1088\u20131100","journal-title":"Blood Adv"},{"key":"1830_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.15252\/emmm.201404698","volume":"7","author":"K Philipp-Abbrederis","year":"2015","unstructured":"Philipp-Abbrederis K, Herrmann K, Knop S et al (2015) In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med 7:477\u2013487","journal-title":"EMBO Mol Med"},{"key":"1830_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13550-020-00681-7","volume":"10","author":"Q Pan","year":"2020","unstructured":"Pan Q, Luo Y, Zhang Y et al (2020) Preliminary evidence of imaging of chemokine receptor-4-targeted PET\/CT with [(68)Ga]pentixafor in non-Hodgkin lymphoma: comparison to [(18)F]FDG. EJNMMI Res 10:89","journal-title":"EJNMMI Res"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-023-01830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-023-01830-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-023-01830-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T01:07:01Z","timestamp":1689037621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-023-01830-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s11307-023-01830-9","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"3 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted according to the guidelines of the Declaration of Helsinki. The need for further ethical review and approval were waived by the local Ethics Committee due to the retrospective character of the study (waiver no. 20210726 02).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Procedures were performed as part of clinical care. Informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"RAW and AKB have received speaker\u2019s honoraria from PentixaPharm. AKB is a member of the advisory board of PentixaPharm. JD has received honoraria from Incyte, Morphosys and Stemline. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}